{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:03:38Z","timestamp":1793412218848,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00109-026-02641-5","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:04:34Z","timestamp":1770224674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Integrated regulation of ferroptosis in prostate cancer covering mechanisms, resistance, and translational opportunities"],"prefix":"10.1007","volume":"104","author":[{"given":"Zhihong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-1894","authenticated-orcid":false,"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"1","key":"2641_CR1","volume":"12","author":"DC Feng","year":"2025","unstructured":"Feng DC, Li DX, Wu RC, Wang J, Xiao YH, Yoo KH, Ye X, Wei WR, Kong DP, Tuo ZT (2025) Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046. Mil Med Res 12(1):12","journal-title":"Mil Med Res"},{"issue":"2","key":"2641_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders G, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouviere O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Tilki D (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","journal-title":"Eur Urol"},{"key":"2641_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/mdr2.70031","author":"X Zhu","year":"2025","unstructured":"Zhu X, Che X, Yang R, Bao B, Chu G (2025) Global, regional, and national burden of cancer in the elderly population, 1990\u20132021: analysis of data from the Global Burden of Disease Study 2021. Med Research. https:\/\/doi.org\/10.1002\/mdr2.70031","journal-title":"Med Research"},{"issue":"9","key":"2641_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101232","volume":"15","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang J, Li D, Wu R, Huang J, Ye L, Tuo Z, Yu Q, Shao F, Wusiman D, Cho WC, Koh SB, Xiong W, Feng D (2025) Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance. J Pharm Anal 15(9):101232","journal-title":"J Pharm Anal"},{"key":"2641_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA (2024) Cancer treatments: past, present, and future. Cancer Genet 286:18\u201324","journal-title":"Cancer Genet"},{"issue":"12","key":"2641_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701\u2013711","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2641_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20230111","volume":"4","author":"D Feng","year":"2024","unstructured":"Feng D, Shi X, Wang J, Zhang L, Xiao Y, Li D, Wu R, Wei W, Miyamoto A, Yoo KH, Ye X, Zhang C, Han P (2024) Telemedicine-medical \u201csnack community\u201d-PHS ecosystem: insights into the double-edged sword role of telemedicine in clinical practice and medical education during the COVID-19 pandemic and beyond. Exploration Beijing 4(4):20230111","journal-title":"Exploration Beijing"},{"issue":"1","key":"2641_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1515\/jtim-2025-0004","volume":"13","author":"Z Guo","year":"2025","unstructured":"Guo Z, Liu Y, Chen D, Sun Y, Li D, Meng Y, Zhou Q, Zeng F, Deng G, Chen X (2025) Targeting regulated cell death: apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity. J Transl Int Med 13(1):10\u201332","journal-title":"J Transl Int Med"},{"issue":"1","key":"2641_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.101050","volume":"15","author":"T Wu","year":"2025","unstructured":"Wu T, Ji M, Li T, Luo L (2025) The molecular and metabolic landscape of ferroptosis in respiratory diseases: pharmacological aspects. J Pharm Anal 15(1):101050","journal-title":"J Pharm Anal"},{"issue":"4","key":"2641_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1644","volume":"16","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zou L, Li X, Guo L, Hu B, Ye H, Liu Y (2024) SLC40A1 in iron metabolism, ferroptosis, and disease: a review. WIREs Mech Dis 16(4):e1644","journal-title":"WIREs Mech Dis"},{"issue":"1-2","key":"2641_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156(1\u20132):317\u201331. https:\/\/doi.org\/10.1016\/j.cell.2013.12.010","journal-title":"Cell"},{"issue":"2","key":"2641_CR12","first-page":"239","volume":"1","author":"M Yan","year":"2025","unstructured":"Yan M, Zhang J, Ji G, Fang X, Mo C (2025) Ferroptosis in pneumoconiosis: from molecular and cellular mechanisms to therapeutic strategies. Med Res 1(2):239\u2013256","journal-title":"Med Res"},{"issue":"8","key":"2641_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12(8):599\u2013620","journal-title":"Protein Cell"},{"issue":"1","key":"2641_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2478\/jtim-2023-0137","volume":"12","author":"W Lai","year":"2024","unstructured":"Lai W, Wang B, Huang R, Zhang C, Fu P, Ma L (2024) Ferroptosis in organ fibrosis: from mechanisms to therapeutic medicines. J Transl Intern Med 12(1):22\u201334","journal-title":"J Transl Intern Med"},{"issue":"1","key":"2641_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Trumbach D, Mao G, Qu F, Bayir H, Fullekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JP, Conrad M (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13(1):91\u201398","journal-title":"Nat Chem Biol"},{"issue":"6","key":"2641_CR16","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T (2021) Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res 81(6):1583\u20131594","journal-title":"Cancer Res"},{"key":"2641_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107915","volume":"219","author":"D Lv","year":"2025","unstructured":"Lv D, Shi Y, Kou L, Zhang D, Guo Y, Zhao S (2025) Precision targeting of androgen receptor-ferroptosis crosstalk in prostate cancer: from mechanisms to therapeutic strategies. Pharmacol Res 219:107915","journal-title":"Pharmacol Res"},{"issue":"1","key":"2641_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01430-0","volume":"9","author":"J Liang","year":"2023","unstructured":"Liang J, Liao Y, Wang P, Yang K, Wang Y, Wang K, Zhong B, Zhou D, Cao Q, Li J, Zhao Y, Jiang N (2023) Ferroptosis landscape in prostate cancer from molecular and metabolic perspective. Cell Death Discov 9(1):128","journal-title":"Cell Death Discov"},{"issue":"9","key":"2641_CR19","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1878-0261.70083","volume":"19","author":"E Pardella","year":"2025","unstructured":"Pardella E, Comito G, Ippolito L, Pranzini E, Iozzo M, Gangarossa G, Virgilio F, Bua S, Nocentini A, Sandrini G, Lorito N, Bacci M, Nesi G, Spatafora P, Serni S, Supuran CT, Morandi A, Chiarugi P, Giannoni E (2025) Targeting carbonic anhydrase IX\/XII prevents the anti-ferroptotic effect of stromal lactic acid in prostate carcinoma. Mol Oncol 19(9):2515\u20132536","journal-title":"Mol Oncol"},{"issue":"6","key":"2641_CR20","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/cas.15356","volume":"113","author":"B Liu","year":"2022","unstructured":"Liu B, Li X, Wang D, Yu Y, Lu D, Chen L, Lv F, Li Y, Cheng L, Song Y, Xing Y (2022) CEMIP promotes extracellular matrix-detached prostate cancer cell survival by inhibiting ferroptosis. Cancer Sci 113(6):2056\u20132070","journal-title":"Cancer Sci"},{"issue":"10","key":"2641_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101304","volume":"15","author":"X Zhang","year":"2025","unstructured":"Zhang X, Xiang Y, Wang Q, Bai X, Meng D, Wu J, Sun K, Zhang L, Qiang R, Liu W, Zhang X, Qiang J, Liu X, Yang Y (2025) Regulation of iron metabolism in ferroptosis: from mechanism research to clinical translation. J Pharm Anal 15(10):101304","journal-title":"J Pharm Anal"},{"issue":"8","key":"2641_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13644","volume":"57","author":"L Yu","year":"2024","unstructured":"Yu L, Huang K, Liao Y, Wang L, Sethi G, Ma Z (2024) Targeting novel regulated cell death: ferroptosis, pyroptosis and necroptosis in anti-PD-1\/PD-L1 cancer immunotherapy. Cell Prolif 57(8):e13644","journal-title":"Cell Prolif"},{"issue":"1","key":"2641_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06180-4","volume":"23","author":"H Yang","year":"2025","unstructured":"Yang H, Zhang X, Jia Z, Wang H, Wu J, Wei X, Huang Y, Yan W, Lin Y (2025) Targeting ferroptosis in prostate cancer management: molecular mechanisms, multidisciplinary strategies and translational perspectives. J Transl Med 23(1):166","journal-title":"J Transl Med"},{"issue":"3","key":"2641_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13779","volume":"58","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li J, Liu J, Gao Y, Li K, Zhao X, Liu Y, Wang D, Hu X, Wang Z (2025) Ferroptosis in osteoarthritis: towards novel therapeutic strategy. Cell Prolif 58(3):e13779","journal-title":"Cell Prolif"},{"issue":"5","key":"2641_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s13577-022-00754-w","volume":"35","author":"J Ji","year":"2022","unstructured":"Ji J, Li H, Wang W, Yuan B, Shen T (2022) ARPC1A is regulated by STAT3 to inhibit ferroptosis and promote prostate cancer progression. Hum Cell 35(5):1591\u20131601","journal-title":"Hum Cell"},{"key":"2641_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cancergen.2025.06.009","volume":"296-297","author":"G Baskar","year":"2025","unstructured":"Baskar G (2025) GPX4 in triple-negative breast cancer: a key regulator of ferroptosis and therapeutic target. Cancer Genet 296\u2013297:76\u201383. https:\/\/doi.org\/10.1016\/j.cancergen.2025.06.009","journal-title":"Cancer Genet"},{"issue":"1","key":"2641_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05614-5","volume":"14","author":"L Cheng","year":"2023","unstructured":"Cheng L, He Q, Liu B, Chen L, Lv F, Li X, Li Y, Liu C, Song Y, Xing Y (2023) SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4. Cell Death Dis 14(1):74. https:\/\/doi.org\/10.1038\/s41419-023-05614-5","journal-title":"Cell Death Dis"},{"issue":"2","key":"2641_CR28","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13186","volume":"23","author":"P Xu","year":"2022","unstructured":"Xu P, Wang Y, Deng Z, Tan Z, Pei X (2022) MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression. Oncol Lett 23(2):67","journal-title":"Oncol Lett"},{"issue":"6","key":"2641_CR29","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1111\/cas.15763","volume":"114","author":"X Zhao","year":"2023","unstructured":"Zhao X, Zhou T, Wang Y, Bao M, Ni C, Ding L, Sun S, Dong H, Li J, Liang C (2023) Trigred motif 36 regulates neuroendocrine differentiation of prostate cancer via HK2 ubiquitination and GPx4 deficiency. Cancer Sci 114(6):2445\u20132459","journal-title":"Cancer Sci"},{"issue":"13","key":"2641_CR30","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.cell.2023.05.003","volume":"186","author":"D Liang","year":"2023","unstructured":"Liang D, Feng Y, Zandkarimi F, Wang H, Zhang Z, Kim J, Cai Y, Gu W, Stockwell BR, Jiang X (2023) Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 186(13):2748\u201364 e22. https:\/\/doi.org\/10.1016\/j.cell.2023.05.003","journal-title":"Cell"},{"issue":"2","key":"2641_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14712\/fb2022068020059","volume":"68","author":"ZC Shao","year":"2022","unstructured":"Shao ZC, Zhu BH, Huang AF, Su MQ, An LJ, Wu ZP, Jiang YJ, Guo H, Han XQ, Liu CM (2022) Docosahexaenoic acid reverses epithelial-mesenchymal transition and drug resistance by impairing the PI3K\/AKT\/ Nrf2\/GPX4 signalling pathway in docetaxel-resistant PC3 prostate cancer cells. Folia Biol (Praha) 68(2):59\u201371","journal-title":"Folia Biol (Praha)"},{"issue":"5","key":"2641_CR32","first-page":"2615","volume":"16","author":"M Mezzanotte","year":"2024","unstructured":"Mezzanotte M, Stanga S (2024) Brain iron dyshomeostasis and ferroptosis in Alzheimer\u2019s disease pathophysiology: two faces of the same coin. Aging Dis 16(5):2615\u20132640","journal-title":"Aging Dis"},{"key":"2641_CR33","doi-asserted-by":"publisher","first-page":"112168","DOI":"10.1016\/j.cellsig.2025.112168","volume":"136","author":"Y Ma","year":"2025","unstructured":"Ma Y, Liu R, Qi P, Wei S, Ren Z, Zhang A, Fan B (2025) HOXA13 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating SLC7A11 and SLC3A2. Cell Signal 112168. https:\/\/doi.org\/10.1016\/j.cellsig.2025.112168","journal-title":"Cell Signal"},{"issue":"1","key":"2641_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07809-4","volume":"16","author":"M Tang","year":"2025","unstructured":"Tang M, Xue L, Wang B, Jiang Z, Li P, Bu H, Zhao C, Zhang Y, Liu S, Chen X, Liu B, Meng X, Li J (2025) SLC7A11 upregulation via AR and NEDD4L ubiquitination contributes to ferroptosis inhibition and enzalutamide resistance in castration-resistant prostate cancer. Cell Death Dis 16(1):591","journal-title":"Cell Death Dis"},{"issue":"19","key":"2641_CR35","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun R, Yan B, Li H, Ding D, Wang L, Pang J, Ye D, Huang H (2023) Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer Res 83(19):3192\u20133204","journal-title":"Cancer Res"},{"key":"2641_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.862015","volume":"12","author":"X Jiang","year":"2022","unstructured":"Jiang X, Guo S, Xu M, Ma B, Liu R, Xu Y, Zhang Y (2022) TFAP2C-mediated lncRNA PCAT1 inhibits ferroptosis in docetaxel-resistant prostate cancer through c-Myc\/miR-25-3p\/SLC7A11 signaling. Front Oncol 12:862015","journal-title":"Front Oncol"},{"key":"2641_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2021.112376","volume":"220","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Guo S, Wang S, Li X, Hou D, Li H, Wang L, Xu Y, Ma B, Wang H, Jiang X (2021) LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p\/SLC7A11 signaling. Ecotoxicol Environ Saf 220:112376","journal-title":"Ecotoxicol Environ Saf"},{"key":"2641_CR38","doi-asserted-by":"publisher","unstructured":"Jiang H, Zhang H, Jiang S (2024) CircDUSP22 attenuates the ferroptosis of prostate cancer cells via miR-18a-5p\/SLC7A11\/GPX4 signaling. Comb Chem High Throughput Screen.\u00a0https:\/\/doi.org\/10.2174\/0113862073324077240624094140","DOI":"10.2174\/0113862073324077240624094140"},{"issue":"1","key":"2641_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07092-z","volume":"23","author":"Y Liu","year":"2025","unstructured":"Liu Y, Qi Z, Yang S, Li Y, Guo J (2025) ZKSCAN5 transcriptional regulation of APOC1 modulates ferroptosis via PI3K\/AKT\/SREBP2\/SLC1A5 axis. J Transl Med 23(1):1020. https:\/\/doi.org\/10.1186\/s12967-025-07092-z","journal-title":"J Transl Med"},{"key":"2641_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkad051","volume":"12","author":"Z Wei","year":"2024","unstructured":"Wei Z, Yu H, Zhao H, Wei M, Xing H, Pei J, Yang Y, Ren K (2024) Broadening horizons: ferroptosis as a new target for traumatic brain injury. Burns Trauma 12:tkad051","journal-title":"Burns Trauma"},{"key":"2641_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166647","author":"ME Wang","year":"2023","unstructured":"Wang ME, Chen J, Lu Y, Bawcom AR, Wu J, Ou J, Asara JM, Armstrong AJ, Wang Q, Li L, Wang Y, Huang J, Chen M (2023) RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F\/ACSL4 axis. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI166647","journal-title":"J Clin Invest"},{"issue":"5","key":"2641_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1678","volume":"14","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhou Y, Feng Y, Hou W, Chen Y, Xing Z, Zhang Y, Wei Q, Yin Y, Guo J, Hu H (2024) Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clin Transl Med 14(5):e1678","journal-title":"Clin Transl Med"},{"issue":"9-10","key":"2641_CR43","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s10495-024-01941-w","volume":"29","author":"A Fan","year":"2024","unstructured":"Fan A, Li Y, Zhang Y, Meng W, Pan W, Chen M, Ma Z, Chen W (2024) Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis. Apoptosis 29(9\u201310):1679\u201395. https:\/\/doi.org\/10.1007\/s10495-024-01941-w","journal-title":"Apoptosis"},{"issue":"14","key":"2641_CR44","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/0008-5472.CAN-23-1489","volume":"84","author":"RK Shrestha","year":"2024","unstructured":"Shrestha RK, Nassar ZD, Hanson AR, Iggo R, Townley SL, Dehairs J, Mah CY, Helm M, Alizadeh-Ghodsi M, Pickering M, Ghesquiere B, Watt MJ, Quek LE, Hoy AJ, Tilley WD, Swinnen JV, Butler LM, Selth LA (2024) ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Res 84(14):2313\u20132332","journal-title":"Cancer Res"},{"issue":"1","key":"2641_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02234-9","volume":"24","author":"X Pan","year":"2025","unstructured":"Pan X, Chen K, Gao W, Xu M, Meng F, Wu M, Wang ZQ, Li YQ, Xu W, Zhang M, Luo Y (2025) Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer. Mol Cancer 24(1):29","journal-title":"Mol Cancer"},{"issue":"3","key":"2641_CR46","doi-asserted-by":"publisher","first-page":"322","DOI":"10.21147\/j.issn.1000-9604.2024.03.08","volume":"36","author":"Z Fan","year":"2024","unstructured":"Fan Z, Dong S, Wang N, Khawar MB, Wang J, Sun H (2024) Unlocking epigenetics for precision treatment of Ewing\u2019s sarcoma. Chin J Cancer Res 36(3):322\u2013340","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"2641_CR47","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/pros.24308","volume":"82","author":"R Zhao","year":"2022","unstructured":"Zhao R, Lv Y, Feng T, Zhang R, Ge L, Pan J, Han B, Song G, Wang L (2022) <article-title update=\"added\">ATF6\u03b1 promotes prostate cancer progression by enhancing PLA2G4A\u2010mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis. Prostate 82(5):617\u201329. https:\/\/doi.org\/10.1002\/pros.24308","journal-title":"Prostate"},{"issue":"8","key":"2641_CR48","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/0008-5472.CAN-23-2796","volume":"85","author":"C Zhang","year":"2025","unstructured":"Zhang C, Ding J, Lim KS, Zhou W, Miao W, Wu S, Liu H, Huang D, Chen C, He H, Xiao J, Xu DF, Shen Y, Huang H, Gao Y (2025) JMJD6 rewires ATF4-dependent glutathione metabolism to confer ferroptosis resistance in SPOP-mutated prostate cancer. Cancer Res 85(8):1496\u20131513","journal-title":"Cancer Res"},{"issue":"1","key":"2641_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02920-w","volume":"43","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Huang Z, Li K, Xie G, Feng Y, Wang Z, Li N, Liu R, Ding Y, Wang J, Yang J, Jia Z (2024) TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression. J Exp Clin Cancer Res 43(1):16. https:\/\/doi.org\/10.1186\/s13046-023-02920-w","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2641_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06464-5","volume":"15","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wu S, Fan J, Meng Z, Gao G, Liu T, Wang Q, Xia H, Wang X, Wu K (2024) CYLD regulates cell ferroptosis through Hippo\/YAP signaling in prostate cancer progression. Cell Death Dis 15(1):79. https:\/\/doi.org\/10.1038\/s41419-024-06464-5","journal-title":"Cell Death Dis"},{"key":"2641_CR51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbrc.2023.02.030","volume":"652","author":"G Yang","year":"2023","unstructured":"Yang G, Pan Q, Lu Y, Zhu J, Gou X (2023) MiR-29a-5p modulates ferroptosis by targeting ferritin heavy chain FTH1 in prostate cancer. Biochem Biophys Res Commun 652:6\u201313","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"2641_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07007-8","volume":"15","author":"G Xie","year":"2024","unstructured":"Xie G, Li N, Li K, Xu Y, Zhang Y, Cao S, Huang B, Liu R, Zhou P, Ding Y, Ding Y, Yang J, Jia Z, Huang Z (2024) Phosphatase LHPP confers prostate cancer ferroptosis activation by modulating the AKT-SKP2-ACSL4 pathway. Cell Death Dis 15(9):665. https:\/\/doi.org\/10.1038\/s41419-024-07007-8","journal-title":"Cell Death Dis"},{"issue":"3","key":"2641_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/rej.2024.0061","volume":"28","author":"C Wang","year":"2025","unstructured":"Wang C, Jiang H (2025) Tripartite motif-containing protein 65 promotes proliferation and inhibits ferroptosis in prostate cancer via enhancing NKD inhibitor of WNT signaling pathway 2 ubiquitination. Rejuvenation Res 28(3):113\u2013124","journal-title":"Rejuvenation Res"},{"issue":"9","key":"2641_CR54","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.21037\/tau-23-605","volume":"13","author":"C Zhao","year":"2024","unstructured":"Zhao C, Liu Z, Peng J, Huang J, Guo J (2024) TRIM47 promotes the Warburg effect and reduces ferroptosis in prostate cancer by FBP1 and FOXO1. Transl Androl Urol 13(9):1991\u20132004","journal-title":"Transl Androl Urol"},{"issue":"3","key":"2641_CR55","first-page":"1155","volume":"15","author":"Q Huang","year":"2024","unstructured":"Huang Q, Wang Y, Chen S, Liang F (2024) Glycometabolic reprogramming of microglia in neurodegenerative diseases: insights from neuroinflammation. Aging Dis 15(3):1155\u20131175","journal-title":"Aging Dis"},{"key":"2641_CR56","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429246636230919122745","volume":"17","author":"M Tavakkoli","year":"2024","unstructured":"Tavakkoli M, Khodashahi R, Aliakbarian M, Rahimi H, Ashrafzadeh K, Ferns G, Khaleghi E, Arjmand MH (2024) Review of the role of metabolic factors in determining the post-surgical adhesion and its therapeutic implications, with a focus on extracellular matrix and oxidative stress. Curr Mol Pharmacol 17:e18761429246636","journal-title":"Curr Mol Pharmacol"},{"key":"2641_CR57","doi-asserted-by":"publisher","DOI":"10.34133\/research.0612","volume":"8","author":"J Wang","year":"2025","unstructured":"Wang J, Shao F, Yu QX, Ye L, Wusiman D, Wu R, Tuo Z, Wang Z, Li D, Cho WC, Wei W, Feng D (2025) The common hallmarks and interconnected pathways of aging, circadian rhythms, and cancer: implications for therapeutic strategies. Research 8:0612. https:\/\/doi.org\/10.34133\/research.0612","journal-title":"Research"},{"issue":"1","key":"2641_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31\u201346","journal-title":"Cancer Discov"},{"issue":"1","key":"2641_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02528-3","volume":"11","author":"G Yu","year":"2025","unstructured":"Yu G, Chen K, Xu B, Cao Q (2025) Mitochondrial SLC25A10 promotes prostate cancer progression by inhibiting ferritinophagy. Cell Death Discov 11(1):242. https:\/\/doi.org\/10.1038\/s41420-025-02528-3","journal-title":"Cell Death Discov"},{"issue":"3","key":"2641_CR60","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1007\/s11357-025-01538-4","volume":"47","author":"CC Wu","year":"2025","unstructured":"Wu CC, Hu SW, Dong SW, Tzou KY, Li CH (2025) The prognostic and neuroendocrine implications of SLC25A29-mediated biomass signature in prostate cancer. Geroscience 47(3):4711\u20134732","journal-title":"Geroscience"},{"issue":"1","key":"2641_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07559-3","volume":"16","author":"W Mei","year":"2025","unstructured":"Mei W, Wei M, Tang C, Li W, Ye B, Xin S, Ma W, Ye L (2025) BCAT2 binding to PCBP1 regulates the PI3K\/AKT signaling pathway to inhibit autophagy-related apoptosis and ferroptosis in prostate cancer. Cell Death Dis 16(1):337","journal-title":"Cell Death Dis"},{"issue":"6","key":"2641_CR62","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.4149\/neo_2022_220626N665","volume":"69","author":"YQ Dai","year":"2022","unstructured":"Dai YQ, Bai Y, Gu J, Fan BY (2022) Stanniocalcin1 knockdown induces ferroptosis and suppresses glycolysis in prostate cancer via the Nrf2 pathway. Neoplasma 69(6):1396\u20131405","journal-title":"Neoplasma"},{"key":"2641_CR63","doi-asserted-by":"publisher","DOI":"10.34133\/research.0791","volume":"8","author":"M Cai","year":"2025","unstructured":"Cai M, Zheng F, Ren YZ, Zhen C, Fu D, Song XL, Li Q, Qu Y, Chen ZS, Zhao SC (2025) New insights into potential therapeutic targets for neuroendocrine prostate cancer: from bench to clinic. Research 8:0791","journal-title":"Research"},{"issue":"4","key":"2641_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14810","volume":"9","author":"T Campbell","year":"2023","unstructured":"Campbell T, Hawsawi O, Henderson V, Dike P, Hwang BJ, Liadi Y, White EZ, Zou J, Wang G, Zhang Q, Bowen N, Scott D, Hinton CV, Odero-Marah V (2023) Novel roles for HMGA2 isoforms in regulating oxidative stress and sensitizing to RSL3-induced ferroptosis in prostate cancer cells. Heliyon 9(4):e14810","journal-title":"Heliyon"},{"key":"2641_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150859","volume":"736","author":"PE Dike","year":"2024","unstructured":"Dike PE, Hwang BJ, Campbell T, Awolowo M, Elliott B, Odero-Marah V (2024) HMGA2 regulates GPX4 expression and ferroptosis in prostate cancer cells. Biochem Biophys Res Commun 736:150859","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2641_CR66","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10429","volume":"22","author":"S He","year":"2021","unstructured":"He S, Zhang M, Ye Y, Zhuang J, Ma X, Song Y, Xia W (2021) Chac glutathione specific \u03b3\u2011glutamylcyclotransferase 1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing endoplasmic reticulum stress and ferroptosis. Exp Ther Med 22(3):997","journal-title":"Exp Ther Med"},{"key":"2641_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117472","volume":"180","author":"J Lu","year":"2024","unstructured":"Lu J, Zou Q, Li Y, Xiong C, Tao L, Wu J, Qin M, Yang J, He L, Qin M, Dong M, Li Y, Cao S (2024) FTH1P8 induces and transmits docetaxel resistance by inhibiting ferroptosis in prostate cancer. Biomed Pharmacother 180:117472","journal-title":"Biomed Pharmacother"},{"key":"2641_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1139\/bcb-2024-0155","volume":"103","author":"X Chen","year":"2025","unstructured":"Chen X, Yao Y, Gong G, He T, Ma C, Yu J (2025) The potential role of AhR\/NR4A1 in androgen-dependent prostate cancer: focus on TCDD-induced ferroptosis. Biochem Cell Biol 103:1\u201311","journal-title":"Biochem Cell Biol"},{"issue":"1","key":"2641_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56494-6","volume":"16","author":"J Yang","year":"2025","unstructured":"Yang J, Lu X, Hao JL, Li L, Ruan YT, An XN, Huang QL, Dong XM, Gao P (2025) VSTM2L protects prostate cancer cells against ferroptosis via inhibiting VDAC1 oligomerization and maintaining mitochondria homeostasis. Nat Commun 16(1):1160","journal-title":"Nat Commun"},{"issue":"8","key":"2641_CR70","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/gtc.12872","volume":"26","author":"P Ogor","year":"2021","unstructured":"Ogor P, Yoshida T, Koike M, Kakizuka A (2021) VCP relocalization limits mitochondrial activity, GSH depletion and ferroptosis during starvation in PC3 prostate cancer cells. Genes Cells 26(8):570\u2013582","journal-title":"Genes Cells"},{"issue":"1","key":"2641_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00822-x","volume":"13","author":"FH Ji","year":"2025","unstructured":"Ji FH, Qian YH, Guo XC, Liao HH, Huang JC, Xu ZH, Yu MM, Wu YY, Bao JW, Chen HJ, Yu YJ, Wang L (2025) Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer. Biomark Res 13(1):109","journal-title":"Biomark Res"},{"key":"2641_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103392","volume":"77","author":"W Lai","year":"2024","unstructured":"Lai W, Zhu W, Wu J, Huang J, Li X, Luo Y, Wang Y, Zeng H, Li M, Qiu X, Wen X (2024) Hjurp inhibits sensitivity to ferroptosis inducers in prostate cancer cells by enhancing the peroxidase activity of PRDX1. Redox Biol 77:103392","journal-title":"Redox Biol"},{"key":"2641_CR73","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2024.1404","author":"L Qin","year":"2024","unstructured":"Qin L, Liang T, Zhu X, Hu W, Li B, Wei M, Zhang J, Li J, Wang J (2024) Senescent macrophages and the lung cancer microenvironment: a new perspective on tumor immune evasion. Aging Dis. https:\/\/doi.org\/10.14336\/AD.2024.1404","journal-title":"Aging Dis"},{"issue":"1","key":"2641_CR74","volume":"11","author":"DC Feng","year":"2024","unstructured":"Feng DC, Zhu WZ, Wang J, Li DX, Shi X, Xiong Q, You J, Han P, Qiu S, Wei Q, Yang L (2024) The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Mil Med Res 11(1):21","journal-title":"Mil Med Res"},{"key":"2641_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104705","volume":"210","author":"D Li","year":"2025","unstructured":"Li D, Wang J, Li X, Wang Z, Yu Q, Koh SB, Wu R, Ye L, Guo Y, Okoli U, Pati-Alam A, Mota E, Wei W, Yoo KH, Cho WC, Feng D, Heavey S (2025) Interactions between radiotherapy resistance mechanisms and the tumor microenvironment. Crit Rev Oncol Hematol 210:104705","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2641_CR76","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imm.13456","volume":"168","author":"D Feng","year":"2023","unstructured":"Feng D, Xiong Q, Wei Q, Yang L (2023) Cellular landscape of tumour microenvironment in prostate cancer. Immunology 168(2):199\u2013202","journal-title":"Immunology"},{"issue":"2","key":"2641_CR77","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 18(2):99\u2013115","journal-title":"Nat Rev Drug Discov"},{"issue":"27","key":"2641_CR78","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41388-024-03057-6","volume":"43","author":"J Zhao","year":"2024","unstructured":"Zhao J, Shen J, Mao L, Yang T, Liu J, Hongbin S (2024) Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer. Oncogene 43(27):2104\u20132114","journal-title":"Oncogene"},{"issue":"4","key":"2641_CR79","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","volume":"21","author":"TR Cox","year":"2021","unstructured":"Cox TR (2021) The matrix in cancer. Nat Rev Cancer 21(4):217\u2013238","journal-title":"Nat Rev Cancer"},{"key":"2641_CR80","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.2147\/OTT.S249752","volume":"13","author":"D Liao","year":"2020","unstructured":"Liao D, Yang G, Yang Y, Tang X, Huang H, Shao J, Pan Q (2020) Identification of pannexin 2 as a novel marker correlating with ferroptosis and malignant phenotypes of prostate cancer cells. Onco Targets Ther 13:4411\u20134421","journal-title":"Onco Targets Ther"},{"issue":"9","key":"2641_CR81","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.21037\/tau-24-415","volume":"13","author":"H Wang","year":"2024","unstructured":"Wang H, Fang D, Zhu J, Liu L, Xue L, Wang L, Karzai F, Antonarakis ES, Urabe F, Ma W, Wei W (2024) Ferroptosis-related gene signature predicts prognosis and immune microenvironment in prostate cancer. Transl Androl Urol 13(9):2092\u20132109","journal-title":"Transl Androl Urol"},{"issue":"1","key":"2641_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97045-9","volume":"15","author":"Y Shao","year":"2025","unstructured":"Shao Y, Li X, Liu J, Qiu Z, Zhang T, Li N, Hu J, Lu F, Zhu Z (2025) Identification of a ferroptosis related genes signature and GDF15 contributing to a new perspective for the diagnosis of CRPC. Sci Rep 15(1):21624","journal-title":"Sci Rep"},{"issue":"1","key":"2641_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02078-1","volume":"16","author":"Y Xie","year":"2025","unstructured":"Xie Y, Zhang S, Wu Y, Qi Y, Qi S, Chen X, Chen B (2025) Pan-cancer analysis predicts MBOAT2 as a potential new ferroptosis related gene immune checkpoint. Discov Oncol 16(1):322","journal-title":"Discov Oncol"},{"key":"2641_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.975623","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Fan J, Chen T, Xu L, Liu P, Xiao L, Wu T, Zhou Q, Zheng Q, Liu C, Chan FL, Wu D (2022) A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer. Front Endocrinol (Lausanne) 13:975623","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2641_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01293-5","author":"Y Song","year":"2024","unstructured":"Song Y, Zhang Q (2024) Development of a novel risk signature for predicting the prognosis and immunotherapeutic response of prostate cancer by integrating ferroptosis and immune-related genes. Mol Biotechnol. https:\/\/doi.org\/10.1007\/s12033-024-01293-5","journal-title":"Mol Biotechnol"},{"issue":"1","key":"2641_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23495","volume":"10","author":"D Feng","year":"2024","unstructured":"Feng D, Tuo Z, Wang J, Ye L, Li D, Wu R, Wei W, Yang Y, Zhang C (2024) Establishment of novel ferroptosis-related prognostic subtypes correlating with immune dysfunction in prostate cancer patients. Heliyon 10(1):e23495","journal-title":"Heliyon"},{"issue":"8","key":"2641_CR87","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.21037\/tau-22-454","volume":"11","author":"BY Yang","year":"2022","unstructured":"Yang BY, Zhao MS, Shi MJ, Lv JC, Tian Y, Zhu YC, Zhao FZ, Li XH, Song J (2022) Establishment of a novel prognostic prediction model through bioinformatics analysis for prostate cancer based on ferroptosis-related genes and its application in immune cell infiltration. Transl Androl Urol 11(8):1130\u20131147","journal-title":"Transl Androl Urol"},{"key":"2641_CR88","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8295113","volume":"2023","author":"C Sun","year":"2023","unstructured":"Sun C, Zhang N, Hu Q, Xia G (2023) Ferroptosis-related prognostic gene LAMP2 is a potential biomarker differential expressed in castration resistant prostate cancer. Dis Markers 2023:8295113. https:\/\/doi.org\/10.1155\/2023\/8295113","journal-title":"Dis Markers"},{"issue":"6","key":"2641_CR89","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.asjsur.2022.12.077","volume":"46","author":"X Shi","year":"2023","unstructured":"Shi X, Feng D, Han P, Wei W (2023) Ferroptosis-related ACSL3 and ACTC1 predict metastasis-free survival for prostate cancer patients undergoing radical radiotherapy. Asian J Surg 46(6):2489\u20132490","journal-title":"Asian J Surg"},{"issue":"1","key":"2641_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01215-2","volume":"28","author":"D Feng","year":"2023","unstructured":"Feng D, Li L, Li D, Wu R, Zhu W, Wang J, Ye L, Han P (2023) Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients. Eur J Med Res 28(1):245. https:\/\/doi.org\/10.1186\/s40001-023-01215-2","journal-title":"Eur J Med Res"},{"issue":"1","key":"2641_CR91","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12967-025-06457-8","volume":"23","author":"R Zhuang","year":"2025","unstructured":"Zhuang R, Xie R, Peng S, Zhou Q, Lin W, Ou Y, Chen B, Su T, Li Z, Huang H, Li K, Duan Y (2025) An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer. J Transl Med 23(1):480","journal-title":"J Transl Med"},{"issue":"1","key":"2641_CR92","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02484-5","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Dai Z, Gao Y, Zhao Z, Li Z, Wang L, Gao X, Qiu Q, Qiu X, Liu Z (2025) Development of a machine learning-based predictive risk model combining fatty acid metabolism and ferroptosis for immunotherapy response and prognosis in prostate cancer. Discov Oncol 16(1):744","journal-title":"Discov Oncol"},{"issue":"2","key":"2641_CR93","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/tox.23997","volume":"39","author":"B Cheng","year":"2024","unstructured":"Cheng B, Lai Y, Huang H, Peng S, Tang C, Chen J, Luo T, Wu J, He H, Wang Q, Huang H (2024) MT1G, an emerging ferroptosis-related gene: a novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer. Environ Toxicol 39(2):927\u2013941","journal-title":"Environ Toxicol"},{"issue":"1","key":"2641_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00715-1","volume":"14","author":"G Jia","year":"2023","unstructured":"Jia G, Wu W, Chen L, Yu Y, Tang Q, Liu H, Jiang Q, Han B (2023) HSF1 is a novel prognostic biomarker in high-risk prostate cancer that correlates with ferroptosis. Discov Oncol 14(1):107. https:\/\/doi.org\/10.1007\/s12672-023-00715-1","journal-title":"Discov Oncol"},{"key":"2641_CR95","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf220","author":"Y Lin","year":"2025","unstructured":"Lin Y, Jia Z, Wu J, Yang H, Chen X, Wang H, Wei X, Yan W, Qi X, Huang Y (2025) Knowledge-guided multi-level network modeling with experimental characterization identifies PRKCA as a novel biomarker and tumor suppressor triggering ferroptosis in prostate cancer. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbaf220","journal-title":"Brief Bioinform"},{"issue":"1","key":"2641_CR96","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1186\/s12885-022-09876-8","volume":"22","author":"C Liu","year":"2022","unstructured":"Liu C, Gao Y, Ni J, Chen S, Hu Q, Wang C, Hu M, Chen M (2022) The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer. BMC Cancer 22(1):788","journal-title":"BMC Cancer"},{"key":"2641_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118067","volume":"299","author":"L Xu","year":"2025","unstructured":"Xu L, Wang X, Xu Y, Wang Z, Li H, Che Z (2025) Discovery of a selenium-containing compound as a promising ferroptosis inducer attenuates prostate cancer progression. Eur J Med Chem 299:118067","journal-title":"Eur J Med Chem"},{"issue":"3","key":"2641_CR98","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mdr2.70025","volume":"1","author":"Z Yang","year":"2025","unstructured":"Yang Z, Song L, Chen H, Chen Y, Xie Y, Xie J (2025) Exploring the potential anticancer effects of Lobelia chinensis Lour in liver cancer via multiomics analysis. Med Research 1(3):483\u20138. https:\/\/doi.org\/10.1002\/mdr2.70025","journal-title":"Med Research"},{"issue":"5","key":"2641_CR99","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2174\/1874467215666220705142954","volume":"16","author":"J Singh","year":"2023","unstructured":"Singh J, Luqman S, Meena A (2023) Carvacrol as a prospective regulator of cancer targets\/signalling pathways. Curr Mol Pharmacol 16(5):542\u2013558","journal-title":"Curr Mol Pharmacol"},{"issue":"3","key":"2641_CR100","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2174\/1874467215666220616145216","volume":"16","author":"H Kowsari","year":"2023","unstructured":"Kowsari H, Davoodvandi A, Dashti F, Mirazimi SMA, Bahabadi ZR, Aschner M, Sahebkar A, Gilasi HR, Hamblin MR, Mirzaei H (2023) Resveratrol in cancer treatment with a focus on breast cancer. Curr Mol Pharmacol 16(3):346\u2013361","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"2641_CR101","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13020-025-01130-0","volume":"20","author":"L Li","year":"2025","unstructured":"Li L, Lu J, Fu S, Li W, Wang Y, Wang K, Tao Y, Liu S (2025) Evodiamine induces ferroptosis in prostate cancer cells by inhibiting TRIM26-mediated stabilization of GPX4. Chin Med 20(1):71","journal-title":"Chin Med"},{"key":"2641_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202500968","author":"A Xu","year":"2025","unstructured":"Xu A, Xie Y, Han R, Zhong J, Wang Q, Zhou Q (2025) Dihydrochelerythrine induced ferroptosis via glutathione peroxidase 4 downregulation in prostate cancer cells. Chem Biodivers. https:\/\/doi.org\/10.1002\/cbdv.202500968","journal-title":"Chem Biodivers"},{"key":"2641_CR103","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.7976","author":"Y Yang","year":"2021","unstructured":"Yang Y, Liu T, Hu C, Xia H, Liu W, Chen J, Wu S, Jiang Y, Xu Y, Liu W, Zhao L (2021) Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration\u2011resistant prostate cancer. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2021.7976","journal-title":"Oncol Rep"},{"issue":"4","key":"2641_CR104","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.apsb.2025.02.023","volume":"15","author":"D Feng","year":"2025","unstructured":"Feng D, Zhang J, Niu H, Zheng X, Jia M, Lu Q, Wang J, Guo W, Sun Q, Yuan H, Lou H (2025) Spermidine inactivates proteasome activity and enhances ferroptosis in prostate cancer. Acta Pharm Sin B 15(4):2095\u20132113","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"2641_CR105","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/pros.24642","volume":"84","author":"W Fu","year":"2024","unstructured":"Fu W, Xu L, Chen Y, Zhang Z, Chen S, Li Q, You X (2024) Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy. Prostate 84(3):223\u2013236","journal-title":"Prostate"},{"issue":"1","key":"2641_CR106","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13020-024-00881-6","volume":"19","author":"S Liu","year":"2024","unstructured":"Liu S, Tao Y, Wu S, Lin J, Fu S, Lu J, Zhang J, Fu B, Zhang E, Xu J, Wang J, Li L, Zhang L, Wang Z (2024) Sanguinarine chloride induces ferroptosis by regulating ROS\/BACH1\/HMOX1 signaling pathway in prostate cancer. Chin Med 19(1):7","journal-title":"Chin Med"},{"issue":"4","key":"2641_CR107","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2174\/1874467215666220819143105","volume":"16","author":"M Ikram","year":"2023","unstructured":"Ikram M, Rasheed S (2023) Genetics of Dravet syndrome and its targeted therapy by nanomedicine: a roadmap for future treatment of drug resistant seizures. Curr Mol Pharmacol 16(4):475\u2013493","journal-title":"Curr Mol Pharmacol"},{"issue":"33","key":"2641_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401095","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Li H, Zhang K, Xu C, Wang J, Li Z, Zhou Y, Liu S, Zhao X, Li Z, Yang F, Hu W, Jing Y, Wu P, Zhang J, Shi C, Zhang R, Jiang W, Xing N, Wen W, Han D, Qin W (2024) Genetically engineered membrane-coated nanoparticles for enhanced prostate-specific membrane antigen targeting and ferroptosis treatment of castration-resistant prostate cancer. Adv Sci 11(33):e2401095","journal-title":"Adv Sci"},{"issue":"8","key":"2641_CR109","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1039\/D0MH01992E","volume":"8","author":"H Wang","year":"2021","unstructured":"Wang H, Zhang L, Miao Z, Zhang M, Liu H, He Q, Meng J, Wen L, Ke Z, Zha Z, Lin R, Liang C (2021) PSMA-targeted arsenic nanosheets: a platform for prostate cancer therapy via ferroptosis and ATM deficiency-triggered chemosensitization. Mater Horiz 8(8):2216\u20132229","journal-title":"Mater Horiz"},{"key":"2641_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102317","volume":"35","author":"L He","year":"2025","unstructured":"He L, Liang H, Wang J, Liu A, Li L, Lu J, Wang Z, Whittaker AK, Lin Q (2025) Multifunctional nanoplatform as nano-inducer of ferroptosis for targeted recognition and imaging-guided therapy of metastatic prostate cancer. Mater Today Bio 35:102317. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102317","journal-title":"Mater Today Bio"},{"issue":"3","key":"2641_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301345","volume":"13","author":"Y Guan","year":"2024","unstructured":"Guan Y, Lei H, Xing C, Yan B, Lin B, Yang X, Huang H, Kang Y, Pang J (2024) Multimodal nanoplatform with ROS amplification to overcome multidrug resistance in prostate cancer via targeting P-glycoprotein and ferroptosis. Adv Healthc Mater 13(3):e2301345","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"2641_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02152-7","volume":"10","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu C, Yang Y, Ren H, Ren T, Huang Y, Zhang S, Sun Q, Huang H (2024) TRIB3 inhibition by palbociclib sensitizes prostate cancer to ferroptosis via downregulating SOX2\/SLC7A11 expression. Cell Death Discov 10(1):425","journal-title":"Cell Death Discov"},{"key":"2641_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105305","volume":"164","author":"X Zhou","year":"2021","unstructured":"Zhou X, Zou L, Chen W, Yang T, Luo J, Wu K, Shu F, Tan X, Yang Y, Cen S, Li C, Mao X (2021) Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacol Res 164:105305","journal-title":"Pharmacol Res"},{"issue":"29","key":"2641_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202504192","volume":"12","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Song XW, Zhang N, Li XH, Wu FC, Wei YA, Xu DL, Xu LF, Yuan FW (2025) Ezetimibe engineered L14-8 suppresses advanced prostate cancer by activating PLK1\/TP53-SAT1-induced ferroptosis. Adv Sci Weinh 12(29):e04192","journal-title":"Adv Sci Weinh"},{"key":"2641_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1594419","volume":"16","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Zhang M, Sun M (2025) ACSL4 at the helm of the lipid peroxidation ship: a deep-sea exploration towards ferroptosis. Front Pharmacol 16:1594419","journal-title":"Front Pharmacol"},{"issue":"1","key":"2641_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbad001","volume":"6","author":"T Guo","year":"2023","unstructured":"Guo T, Yuan Z, Wang T, Zhang J, Tang H, Zhang N, Wang X, Chen S (2023) Integrative analysis of ferroptosis regulators for clinical prognosis based on deep learning and potential chemotherapy sensitivity of prostate cancer. Precis Clin Med 6(1):pbad001","journal-title":"Precis Clin Med"},{"issue":"3","key":"2641_CR117","doi-asserted-by":"publisher","first-page":"446","DOI":"10.21147\/j.issn.1000-9604.2025.03.12","volume":"37","author":"J Zou","year":"2025","unstructured":"Zou J, Wang S, Zhang Y, Tian W, Mai G, Xu Y, Xiao W, Graves EE, Wu F (2025) Tumor-educated cells in tumor microenvironment: key drivers of immunotherapy resistance. Chin J Cancer Res 37(3):446\u2013465","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"2641_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06246-3","volume":"23","author":"K Zhang","year":"2025","unstructured":"Zhang K, Guo L, Li X, Hu Y, Luo N (2025) Cancer-associated fibroblasts promote doxorubicin resistance in triple-negative breast cancer through enhancing ZFP64 histone lactylation to regulate ferroptosis. J Transl Med 23(1):247","journal-title":"J Transl Med"},{"issue":"2","key":"2641_CR119","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21147\/j.issn.1000-9604.2024.02.05","volume":"36","author":"S Chen","year":"2024","unstructured":"Chen S, Sun J, Zhou H, Lei H, Zang D, Chen J (2024) New roles of tumor-derived exosomes in tumor microenvironment. Chin J Cancer Res 36(2):151\u2013166","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"2641_CR120","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12964-023-01369-w","volume":"22","author":"L Liu","year":"2024","unstructured":"Liu L, Ye Y, Lin R, Liu T, Wang S, Feng Z, Wang X, Cao H, Chen X, Miao J, Liu Y, Jiang K, Han Z, Li Z, Cao X (2024) Ferroptosis: a promising candidate for exosome-mediated regulation in different diseases. Cell Commun Signal 22(1):6","journal-title":"Cell Commun Signal"},{"issue":"2","key":"2641_CR121","first-page":"257","volume":"1","author":"J Li","year":"2025","unstructured":"Li J, Peng J, Wang J, Chen Z (2025) The dual role of exosomes in the tumor microenvironment: from pro-tumorigenic signaling to immune modulation. Med Res 1(2):257\u2013284","journal-title":"Med Res"},{"issue":"7755","key":"2641_CR122","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W (2019) CD8(+) t cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569(7755):270\u2013274","journal-title":"Nature"},{"key":"2641_CR123","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jconrel.2024.01.051","volume":"367","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Yin W, Yang Z, Sun J, Chang J, Huang L, Xue L, Zhang X, Zhi H, Chen S, Chen N, Li Y (2024) Nanotechnology-enabled M2 macrophage polarization and ferroptosis inhibition for targeted inflammatory bowel disease treatment. J Control Release 367:339\u2013353","journal-title":"J Control Release"},{"key":"2641_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202514077","author":"S Shao","year":"2025","unstructured":"Shao S, Li W, Hong Y, Zeng R, Zhu L, Yi L, Li Y, Wang Y, Huang H, Jiang X, Jin X (2025) ZDHHC2-dependent palmitoylation dictates ferroptosis and castration sensitivity in prostate cancer via controlling ACSL4 degradation and lipid peroxidation. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202514077","journal-title":"Adv Sci"},{"issue":"4","key":"2641_CR125","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22(4):266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2641_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00267","volume":"14","author":"X Song","year":"2020","unstructured":"Song X, Long D (2020) Nrf2 and ferroptosis: a new research direction for neurodegenerative diseases. Front Neurosci 14:267. https:\/\/doi.org\/10.3389\/fnins.2020.00267","journal-title":"Front Neurosci"},{"key":"2641_CR127","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkae054","volume":"12","author":"R Yang","year":"2024","unstructured":"Yang R, Zhou S, Huang J, Kang D, Chen Y, Wang X, Shi Y, Wang Z (2024) The role of Q10 engineering mesenchymal stem cell-derived exosomes in inhibiting ferroptosis for diabetic wound healing. Burns Trauma 12:tkae054","journal-title":"Burns Trauma"},{"key":"2641_CR128","volume":"8","author":"X Wang","year":"2025","unstructured":"Wang X, Wu Z, Xu L, Lou L, Yang Y, Zhang J, Miao H, Xia C, Peng Z, Yang D, Tao Z, Meng X, Liu W, Yuan M, Wang J, Fei W, Dai J (2025) Human amniotic epithelial stem cell exosomes regulate chondrocyte ferroptosis through ACTA2-AS1-targeted binding to ACSL4 for osteoarthritis intervention. Research Wash D C 8:0814","journal-title":"Research Wash D C"},{"issue":"6","key":"2641_CR129","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20230134","volume":"4","author":"Y Luo","year":"2024","unstructured":"Luo Y, He X, Du Q, Xu L, Xu J, Wang J, Zhang W, Zhong Y, Guo D, Liu Y, Chen X (2024) Metal-based smart nanosystems in cancer immunotherapy. Exploration 4(6):20230134","journal-title":"Exploration"},{"issue":"5","key":"2641_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20230037","volume":"4","author":"Z Cao","year":"2024","unstructured":"Cao Z, Liu J, Yang X (2024) Deformable nanocarriers for enhanced drug delivery and cancer therapy. Exploration 4(5):20230037","journal-title":"Exploration"},{"issue":"1","key":"2641_CR131","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40779-024-00538-3","volume":"11","author":"P Lin","year":"2024","unstructured":"Lin P, Gan YB, He J, Lin SE, Xu JK, Chang L, Zhao LM, Zhu J, Zhang L, Huang S, Hu O, Wang YB, Jin HJ, Li YY, Yan PL, Chen L, Jiang JX, Liu P (2024) Advancing skeletal health anddisease research with single-cell RNA sequencing. Mil Med Res. 11(1):33. https:\/\/doi.org\/10.1186\/s40779-024-00538-3","journal-title":"Mil Med Res."},{"key":"2641_CR132","doi-asserted-by":"publisher","unstructured":"Du Z, Shi Y, Tan J. Advances in integrating single-cell sequencing data to unravel the mechanism of ferroptosis in cancer. Brief Funct Genomics. 2024;23(6):713-25.\nhttps:\/\/doi.org\/10.1093\/bfgp\/elae025","DOI":"10.1093\/bfgp\/elae025"},{"key":"2641_CR133","doi-asserted-by":"publisher","unstructured":"Ding T, He L, Lin G, Xu L, Zhu Y, Wang X, Liu X, Guo J, Lei F, Zuo Z, Zheng J. Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer. Chin J Cancer Res. 2025;37(1):90-114. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.01.07","DOI":"10.21147\/j.issn.1000-9604.2025.01.07"},{"key":"2641_CR134","doi-asserted-by":"publisher","unstructured":"Kim JW, Lee JY, Oh M, Lee EW. An integrated view of lipid metabolism in ferroptosis revisited via lipidomic analysis. Exp Mol Med. 2023;55(8):1620-31. https:\/\/doi.org\/10.1038\/s12276-023-01077-y","DOI":"10.1038\/s12276-023-01077-y"},{"key":"2641_CR135","doi-asserted-by":"publisher","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1","DOI":"10.1038\/s41586-019-1730-1"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02641-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02641-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02641-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:03:52Z","timestamp":1770228232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02641-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2641"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02641-5","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}